This is a study that will follow transplant patients from Study A3921030 to monitor for long term safety, tolerability and efficacy for 5 additional years, except in Portugal where the study will follow transplant patients through Month 36 posttransplant. Patients will continue their study medications that were previously assigned.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Kaplan-Meier Analysis of Percentage of Participants With Clinically Significant Infection by Visit
Timeframe: Months 12, 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72
Percentage of Participants With Malignancies
Timeframe: Months 12 through 72.
Least Squares Means of Measured Glomerular Filtration Rate (GFR) (Iohexol Serum Clearance in Milliliters Per Minute [mL/Min])
Timeframe: Month 36
Percentage of Participants With Progression of Chronic Allograft Lesions at Month 36
Timeframe: Month 36
Kaplan-Meier Analysis of Percentage of Participants With First Biopsy Proven Acute Rejection (BPAR) by Visit
Timeframe: Months 12, 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72
Kaplan-Meier Analysis of Percentage of Participants With Treated Clinical Acute Rejection by Visit
Timeframe: Months 12, 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72